BACKGROUND: Higher intake of calcium and vitamin D has been associated with a reduced risk of colorectal cancer in epidemiologic studies and polyp recurrence in polyp-prevention trials. However, randomized-trial evidence that calcium with vitamin D supplementation is beneficial in the primary prevention of colorectal cancer is lacking. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 36,282 postmenopausal women from 40 Women's Health Initiative centers: 18,176 women received500 mg of elemental calcium as calcium carbonate with 200 IU of vitamin D3 [corrected] twice daily (1000 mg of elemental calcium and 400 IU of vitamin D3) and 18,106 received a matching placebo for an average of 7.0 years. The incidence of pathologically confirmed colorectal cancer was the designated secondary outcome. Baseline levels of serum 25-hydroxyvitamin D were assessed in a nested case-control study. RESULTS: The incidence of invasive colorectal cancer did not differ significantly between women assigned to calcium plus vitamin D supplementation and those assigned to placebo (168 and 154 cases; hazard ratio, 1.08; 95 percent confidence interval, 0.86 to 1.34; P=0.51), and the tumor characteristics were similar in the two groups. The frequency of colorectal-cancer screening and abdominal symptoms was similar in the two groups. There were no significant treatment interactions with baseline characteristics. CONCLUSIONS: Daily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women. The long latency associated with the development of colorectal cancer, along with the seven-year duration of the trial, may have contributed to this null finding. Ongoing follow-up will assess the longer-term effect of this intervention. (ClinicalTrials.gov number, NCT00000611.). Copyright 2006 Massachusetts Medical Society.
RCT Entities:
BACKGROUND: Higher intake of calcium and vitamin D has been associated with a reduced risk of colorectal cancer in epidemiologic studies and polyp recurrence in polyp-prevention trials. However, randomized-trial evidence that calcium with vitamin D supplementation is beneficial in the primary prevention of colorectal cancer is lacking. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 36,282 postmenopausal women from 40 Women's Health Initiative centers: 18,176 women received 500 mg of elemental calcium as calcium carbonate with 200 IU of vitamin D3 [corrected] twice daily (1000 mg of elemental calcium and 400 IU of vitamin D3) and 18,106 received a matching placebo for an average of 7.0 years. The incidence of pathologically confirmed colorectal cancer was the designated secondary outcome. Baseline levels of serum 25-hydroxyvitamin D were assessed in a nested case-control study. RESULTS: The incidence of invasive colorectal cancer did not differ significantly between women assigned to calcium plus vitamin D supplementation and those assigned to placebo (168 and 154 cases; hazard ratio, 1.08; 95 percent confidence interval, 0.86 to 1.34; P=0.51), and the tumor characteristics were similar in the two groups. The frequency of colorectal-cancer screening and abdominal symptoms was similar in the two groups. There were no significant treatment interactions with baseline characteristics. CONCLUSIONS: Daily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women. The long latency associated with the development of colorectal cancer, along with the seven-year duration of the trial, may have contributed to this null finding. Ongoing follow-up will assess the longer-term effect of this intervention. (ClinicalTrials.gov number, NCT00000611.). Copyright 2006 Massachusetts Medical Society.
Authors: Azra Kurbasic; Alaitz Poveda; Yan Chen; Asa Agren; Elisabeth Engberg; Frank B Hu; Ingegerd Johansson; Ines Barroso; Anders Brändström; Göran Hallmans; Frida Renström; Paul W Franks Journal: Curr Nutr Rep Date: 2014-12-01
Authors: Chris R Cardwell; Christian C Abnet; Philip Veal; Carmel M Hughes; Marie M Cantwell; Liam J Murray Journal: Int J Cancer Date: 2012-01-11 Impact factor: 7.396
Authors: María Elena Martínez; Elizabeth T Jacobs; John A Baron; James R Marshall; Tim Byers Journal: J Natl Cancer Inst Date: 2012-04-25 Impact factor: 13.506
Authors: Veronika Fedirko; Roberd M Bostick; Michael Goodman; W Dana Flanders; Myron D Gross Journal: Am J Epidemiol Date: 2010-07-22 Impact factor: 4.897
Authors: David A Hanley; Ann Cranney; Glenville Jones; Susan J Whiting; William D Leslie; David E C Cole; Stephanie A Atkinson; Robert G Josse; Sidney Feldman; Gregory A Kline; Cheryl Rosen Journal: CMAJ Date: 2010-07-12 Impact factor: 8.262
Authors: M Lombardi; I Scattina; C Sardella; C Urbani; E Marciano; S Signori; L Ruocco; G Pellegrini; E Martino; F Bogazzi Journal: J Endocrinol Invest Date: 2013-01-14 Impact factor: 4.256
Authors: Robin T Zon; Elizabeth Goss; Victor G Vogel; Rowan T Chlebowski; Ismail Jatoi; Mark E Robson; Dana S Wollins; Judy E Garber; Powel Brown; Barnett S Kramer Journal: J Clin Oncol Date: 2008-12-15 Impact factor: 44.544